Axon Enterprise vs. DocuSign: Which Industrials Stock Is a Better Buy in 2026?
One trades at 50x forward earnings with 33% growth; the other at 17x with steadier cash generation. The valuation gap raises a critical question for 2026 investors.
When weighing whether to invest in Axon Enterprise (AXON) or Docusign Inc. (DOCU) for the long-term, it's essential to closely examine the fundamentals and outlook of each company. Both firms rely on subscription-based software models, but they operate in distinct industries: Axon offers hardware and cloud services to public safety organizations, while Docusign provides software for digital agreement management.
Axon Enterprise reported $2.8 billion in revenue for the fiscal year ending December 31, 2025, representing a 33.5% year-over-year growth. The company generated $124.9 million in net income, yielding a net margin of approximately 4.5%. As of December 2025, Axon had a current ratio of about 2.5x, indicating strong liquidity to cover short-term obligations, and a debt-to-equity ratio of roughly 0.6x, suggesting a moderate level of financial leverage.
Docusign, on the other hand, posted $3.2 billion in revenue for the fiscal year ending January 31, 2026, with an 8.2% year-over-year increase. The company reported $309 million in net income, resulting in a higher net margin of around 9.6%. As of January 2026, Docusign had a debt-to-equity ratio of approximately 0.1x, indicating a very conservative capital structure. The company's current ratio stands at about 0.7x, which suggests that its short-term assets are less than its short-term liabilities.
When comparing the two companies, Axon Enterprise currently faces higher valuation multiples due to its robust revenue growth and dominant position in the public safety technology market. While Docusign shows promising growth prospects with its expanding software platform and AI-driven initiatives, it may be entering a phase of more mature growth as it navigates intense competition in the digital agreement management space.
In conclusion, investors should carefully weigh Axon's high-growth potential in a specialized market against Docusign's valuation and expansion strategies, considering their long-term growth trajectories and industry dynamics.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
